Revolutionary advances in science and technology are driving change in the business of pharmaceuticals, biotechnology, and medical equipment. Extraordinary new developments in the basic sciences, engineering, and information technology are reshaping the manner in which R&D is conducted, as well as the strategies and futures of large and small commercial firms and other research organizations.
Within the MIT Management of Technology (MOT) Program, we offer a special opportunity for experienced professionals from the biomedical fields to earn a master's degree. This special opportunity integrates scientific and technical capabilities with management education, providing contact with faculty from MIT's Departments of Biology, Chemical Engineering, the Harvard-MIT Division of Health Sciences and Technology, as well as the Sloan School of Management.
Our primary goal is to educate a new generation of leaders who, upon completion of the program, will have developed strong foundations both in management and their relevant biomedical, scientific, or technical discipline. We want our graduates to resume their careers and make important contributions as senior managers of firms and organizations that conduct R&D, develop products, or transfer technology.
The core curriculum is the same as for all students in the Management of Technology program: Strategic Aspects of Technology Management,; Managerial Decision Making; Human and Organizational Factors in Technology Management; Managing Product/Process Development; and Applied Research. In addition, we organize a weekly seminar specifically for students with knowledge or experience in the biomedical industries to discuss the application of this curriculum to biomedicine.
Our focused elective subjects integrate biomedical sciences and technology with the disciplines of management. New offerings by our multidisciplinary faculty during academic year 2000-01 will include "Information Technology and the Biomedical Industries" and "Evaluation of Medical Technology: Clinical and Economic Outcomes Assessment."
The thesis is an opportunity to work closely with faculty to conduct an in-depth analysis of a specific management problem or business opportunity related to the biomedical industries. Some students will opt to continue work begun in the context of the weekly seminar on biomedical sciences and technology management. Theses and seminar projects often address business problems faced by sponsoring companies; others have led to new businesses.
Throughout, students have the opportunity to benefit from close mentoring by the faculty. There are also a number of opportunities for contact with industry leaders from the biomedical fields, while they are guests in classes and seminars, or during field visits to the firms.
In addition to the distinguished faculty for the core MOT Program, we draw from the MIT academic departments and the Harvard-MIT Division of Health Sciences and Technology.
Charles L. Cooney, Professor of Chemical Engineering, MIT Department of Chemical Engineering, and Co-Director, MIT Program on the Pharmaceutical Industry. Dr. Cooney is interested in biochemical engineering as the integration of biological science with engineering principles, a theme that cuts through his current research activities, which include biochemical process control and biochemical product recovery. As co-director of the Program on the Pharmaceutical Industry, Cooney researches issues of competitiveness and productivity of the pharmaceutical industry, with a particular emphasis on manufacturing, management of technology and industry structure.
Robert H. Rubin, M.D., Osborne Chair of Health Sciences and Technology Director, Harvard MIT Center for Experimental Pharmacology and Therapeutics Harvard-MIT Division of Health Sciences and Technology (HST). Dr. Rubin is a practicing physician who serves as Chief of Transplantation and Surgical Infectious Disease at the Massachusetts General Hospital. He has made a major commitment to the development and evaluation of new pharmacologic agents. The author or co-author of more than 300 articles and manuscripts in the areas of his research interests, he has participated extensively in the training of physicians and medical scientists.
Anthony J. Sinskey Professor of Microbiology, MIT Department of Biology. Dr. Sinskey is an authority on biotechnology and business, and has been actively involved in the start-up of new companies and as a consultant to new and established firms. Among his current research interests is the role of combinatorial chemistry in new drug discovery.
These three faculty members, along with Stan N. Finkelstein, M.D., comprise the steering committee for this special opportunity within the MOT Program. Dr. Finkelstein, a Senior Research Scientist at the Sloan School of Management and Co-director of the MIT Program on the Pharmaceutical Industry, is part of the MOT Program's principal teaching faculty. Campus and Other Resources
The MIT Program on the Pharmaceutical Industry is a research and education program focused on understanding the structure and dynamics of the global pharmaceutical industry. POPI research concentrates on the firms that make up that industry, as well as on their customers and government bodies providing oversight of the industry. Through its research, POPI seeks to improve the management of the pharmaceutical industry in the discovery, development, and marketing of new drugs that add value to health and the delivery of medical care.
The HST Center for Experimental Pharmacology and Therapeutics was established as a mechanism for fostering both education and research in therapeutics and experimental pharmacology. The Center's dual mission is to enrich and create educational programs in pharmacology and therapeutics, and to conduct clinical research that is pathophysiologically oriented, patient-centered, quantitative measurement-based, and translational. This multidisciplinary center gives an equal emphasis to experimental therapies and experimental technologies, and also places "practical" strategies and measurements that lead directly to drug development and registration at the core of its work. The Center includes a Clinical Investigation Training Program leading to a Master of Science degree from Harvard.
BPEC is a National Science Foundation Engineering Research Center. Founded in 1985, it has developed prominence in both research and education in biotechnology. The center emphasizes a fundamental but interdisciplinary approach to integrating molecular and cell biology with process engineering with the simultaneous goals of creating advanced biological technologies, focusing on protein and nucleic acid therapeutics, and preparing top-quality individuals for leadership in this industry.
CAMP is a consortium of two universities, MIT and Purdue along with eight member pharmaceutical companies. The drug firms have jointly funded new research projects that address product and process improvements through innovation in pharmaceutical manufacturing.
The Center for Biomedical Engineering (CBE) is creating new research programs at MIT that bring engineering into intimate contact with modern molecular and cell biology, emphasizing the development of innovative health care technologies within the realm of molecular medicine. CBE has organized three major research thrust areas: Molecular Engineering, Cell & Tissue Engineering, and Physiological Systems Engineering.
The wide array of resources available within the MIT/Harvard academic communities is virtually unlimited. Beyond the campuses, the Boston area is a haven both for clinical medicine and high-technology businesses related to biomedicine. Interest in managing biomedical sciences and technology organizations extends from the universities themselves to the teaching hospitals affiliated with Harvard and the other medical schools, to the numerous biotechnology, pharmaceutical, and medical device firms operating in Cambridge and Boston, along Route 128 ("Technology Road"), and in nearby communities.
This special opportunity within the MOT program is designed to develop leaders in the strategic management of biomedical science or technology within industrial firms and other R&D organizations. Applicants will be mature professionals with scientific or technical backgrounds and with work experience beyond university education in the biomedical field. Preference is given to applicants sponsored by their employer organizations.
For specific information on admissions requirements and the application process, please refer to the MIT Management of Technology Program brochure for 2000-01. Further information regarding this program can be obtained from either one of the following persons:
Mr. David Weber Stan N. Finkelstein, M.D.
Management of Technology Program Program on the Pharmaceutical Industry
phone: (617) 253-7161 phone: (617) 253-8014
e-mail: email@example.com e-mail: firstname.lastname@example.org
For more information, comments, or suggestions contact email@example.com